New $50 million commitment will advance blood tests for tau and other co-pathologies, multi-marker panels, and AI-driven biomarkers to accelerate drug development, enable combination therapies, and su ...

Add Yahoo as a preferred source to see more of our stories on Google. Jo Carole Lauder and Jane Lauder at the Alzheimer's Drug Discovery Foundation Fifth Annual Hope on the Horizon Event at The Beach ...

Please provide your email address to receive an email when new articles are posted on . The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate ...

"Combining the MoCA Solo assessment with blood biomarkers has the potential to enable earlier detection of Alzheimer's disease by identifying individuals with MCI who are most likely to benefit from ...

NEW YORK, NY (July 15, 2020) - A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on ...

"Randy embodies exactly what the Goodes Prize was established to recognize: science that changes the trajectory of the field," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF.

The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, ...

Please provide your email address to receive an email when new articles are posted on . A Canadian neuroimaging company has received an investment from the Alzheimer’s Drug Discovery Foundation to ...

NEW YORK, NY (1/5/2021) - Subtle changes in speech and language can be an early warning sign of Alzheimer's -- sometimes appearing long before other more serious symptoms. The challenge is recognizing ...

On Thursday, April 7, the Centers for Medicare and Medicaid (CMS) formalized its plan to cover the anti-amyloid drug Aduhelm only for patients enrolled in clinical trials. However, in response to ...

NEW YORK, March 17, 2026 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional ...